(STOK) – Stoke touts early signs of antisense drug effectiveness in Dravet syndrome
Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 underway at the 2021 American Epilepsy Society annual meeting.
- STK-001 is under development to target the underlying cause of Dravet syndrome, a severe and progressive genetic epilepsy.
- STK-001 was well tolerated in single and multiple doses in 22 patients with Dravet syndrome aged 2 to 18 years.
- 12 of 17 evaluable patients at the time (70.6%) saw reductions from baseline in seizure frequency.
- Median reductions in seizure frequency of 17% to 37% were observed in all cohorts.
- The drug appeared to be well tolerated after 12 weeks, with the most common side effects being headache, vomiting, seizures, irritability, and back pain.
- Although five of 22 patients (22.7%) experienced a serious adverse event, none of them was drug-related.
- MONARCH patients are eligible to continue treatment in the SWALLOWTAIL extension study, which is currently being enrolled.
- Stoke plans to enroll 90 patients in the United States in the MONARCH study.
- Related link: Stoke Therapeutics Releases Encouraging Safety Data From Early-Stage Dravet Syndrome Trial.
- BofA launched the Stoke Therapeutics cover with a buy rating and a price target of $ 43.
- Analyst Greg Harrison adds that Stoke’s developing STK-001 lead program for Dravet syndrome could be the first to treat refractory epilepsy, with a potential for peak sales of over $ 2 billion.
- Price action: STOK shares are down 10.50% to $ 21.35 in Friday’s last check trading session.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.